A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
Status:
Completed
Trial end date:
2016-04-02
Target enrollment:
Participant gender:
Summary
Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients
with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave
symptoms of angina in patients with stable coronary disease that is not suitable for surgical
or percutaneous revascularization. It has been shown that in patients with stable coronary
disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear imaging.
The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion in
patients with dilated cardiomyopathy.